The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.
The company is currently conducting a Phase II trial of BSI-201 in triple- negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme, the most common brain cancer in adults. An additional trial in uterine cancer is expected to begin enrollment in the coming weeks.
Barry Sherman, executive vice president of Development at BiPar, said: “We will soon have patients enrolled in four separate Phase II trials of BSI-201, reflecting the breadth of tumor types that could be sensitive to the drug.”